What is StemoniX?
StemoniX operates at the intersection of biotechnology and advanced computing, specializing in the creation of engineered human brain models. These sophisticated models are designed to replicate complex neurological functions, including memory, learning, and cognition, providing researchers with unprecedented insights into human neural pathways. Through its core offerings, such as CNS-3D and PNS-3D technologies, the firm enables pharmaceutical developers to accelerate the drug discovery process while reducing reliance on traditional, less predictive testing methods. By integrating neural interfacing with high-throughput screening, StemoniX provides a robust framework for identifying potential therapies for neurodegenerative diseases and other complex conditions, positioning itself as an essential partner for global research institutions and biopharmaceutical enterprises.
How much funding has StemoniX raised?
StemoniX has raised a total of $23.3M across 4 funding rounds:
Angel/Seed
$2.5M
Series A
$6M
Series B
$14.4M
Debt
$350K
Angel/Seed (2016): $2.5M, investors not publicly disclosed
Series A (2017): $6M led by Exponential.io
Series B (2019): $14.4M, investors not publicly disclosed
Debt (2020): $350K featuring PPP
Key Investors in StemoniX
Exponential.io
Exponential Group is a technology-focused investment firm that provides strategic capital to software and high-growth enterprises.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for StemoniX?
With the recent influx of capital, StemoniX is well-positioned to scale its operational capacity and expand its footprint in the global drug discovery market. The company is expected to prioritize the refinement of its AI-driven analytical tools, which are essential for interpreting the vast datasets generated by its 3D neural models. Furthermore, strategic expansion into new therapeutic areas remains a primary objective, as the firm seeks to leverage its proprietary technology to address unmet needs in neurological health. As the industry shifts toward more predictive, human-centric research models, StemoniX is poised to capitalize on this transition, potentially setting new standards for efficacy and safety in the development of next-generation neurological therapies.
See full StemoniX company page
